StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) shareholders

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
107M of 99M shares
Institutional holders
310
59 new, 44 sold out
Net institutional buying
9M
In Q2 2026
Insider trades, 12 months
0 buys · 28 sales
Net sold $3.81M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Vanguard Portfolio Management8,481,2668.60%13G (passive) amendmentSep 30, 2026
BlackRock, Inc.8,141,3848.30%13G (passive) amendmentJun 30, 2026
RTW Investments, LP
Joint filing with Roderick Wong (7.90%)
7,796,8957.90%13G (passive)Jun 30, 2026
State Street Corporation
Joint filing with Ssga Funds Management, Inc. (5.40%)
7,538,0787.60%13G (passive)Sep 30, 2026
AQR Capital Management Holdings, LLC
Joint filing with AQR Capital Management, LLC (6.66%)
6,560,8096.66%13G (passive)Jun 30, 2026
Madison Avenue Partners, LP
Joint filing with Madison Avenue International LP (6.40%), EMAI Management, LLC (6.40%) and 3 more
6,307,7986.40%13G (passive)Oct 13, 2026
Vanguard Capital Management5,058,4195.13%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RAREValueChange% of portfolio
BlackRock, Inc.10,654,27610.81%$355.75M+3,354,6780.01%
Rtw Investments, LP7,796,8957.91%$260.34M+4,148,1002.22%
Vanguard Portfolio Management LLC6,790,1356.89%$226.72M+1,404,1430.01%
Aqr Capital Management LLC6,560,8096.65%$214.14M+1,982,7850.07%
State Street Corp6,158,7666.25%$205.64M+1,137,3250.01%
Vanguard Capital Management LLC4,296,4914.36%$143.46M+106,6600.00%
Two Sigma Investments, LP3,621,2003.67%$120.91M+1,415,3800.09%
Sands Capital Management, LLC3,158,3683.20%$105.46M−56,1650.39%
Jacobs Levy Equity Management, Inc2,939,7192.98%$98.16M+1,508,6480.35%
Frontier Capital Management Co LLC2,847,9362.89%$95.09M+656,7540.89%
Geode Capital Management, LLC2,578,8282.62%$86.12M+729,4370.00%
Bellevue Group AG1,982,7752.01%$66.20M−397,2251.39%
D. E. Shaw & Co., Inc.1,730,1931.75%$57.77M+469,1750.03%
Sofinnova Investments, Inc.1,717,5051.74%$57.35M−1,428,3832.96%
Adage Capital Partners Gp, L.L.C.1,580,0001.60%$52.76M+1,100,0000.07%
GW&K Investment Management, LLC1,481,1781.50%$49.46M−134,2480.39%
Mpm Bioimpact LLC1,418,2151.44%$47.35MNew2.89%
Price T Rowe Associates Inc /Md/1,356,5011.38%$45.30M+552,3920.00%
Morgan Stanley1,324,8051.34%$44.24M−175,7230.00%
Wellington Management Group Llp1,250,4641.27%$41.75M−1,390,3480.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026310107M100.0%59 / 11698 / 4428M19M
Q1 202629898M99.6%63 / 12584 / 4942M27M
Q4 202528894M95.3%57 / 11191 / 6519M23M
Q3 2025303100M100.0%53 / 13191 / 5727M21M
Q2 202531094M95.5%54 / 117108 / 4314M10M
Q1 202530090M91.2%34 / 126105 / 4410M7M
Q4 202431388M88.8%55 / 111109 / 4210M10M
Q3 202430287M88.4%59 / 11093 / 2915M11M
Q2 202427589M90.1%47 / 11780 / 4017M9M
Q1 202427081M82.3%53 / 10076 / 207M8M
Q4 202323782M82.8%44 / 9574 / 2317M6M
Q3 202322071M72.3%11 / 10573 / 337M5M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

265 funds held RARE in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of RAREValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF3,666,8683.72%$122.44M1.14%Jun 30, 2026
Vanguard Total Stock Market Index Fund2,986,6213.03%$99.72M0.00%Jun 30, 2026
iShares Russell 2000 ETF2,501,9962.54%$83.54M0.10%Jun 30, 2026
Vanguard Small-Cap Index Fund2,144,8022.18%$71.61M0.04%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund1,238,6401.26%$41.36M0.09%Jun 30, 2026
Vanguard Extended Market Index Fund1,127,7111.14%$37.65M0.04%Jun 30, 2026
Vanguard Strategic Equity Fund1,072,2141.09%$35.80M0.29%Jun 30, 2026
Fidelity Small Cap Index Fund1,055,4931.07%$26.29M0.08%Jul 31, 2026
AQR Long-Short Equity Fund914,7180.93%$30.54M0.39%Jun 30, 2026
Vanguard Explorer Fund821,9860.83%$20.48M0.09%Jul 31, 2026
iShares Biotechnology ETF635,3460.64%$21.21M0.23%Jun 30, 2026
Touchstone Funds Group Trust-Touchstone Sands Capital Select Growth Fund611,9500.62%$20.43M0.92%Jun 30, 2026
Strategic Advisers U.S. Total Stock Fund527,8130.54%$12.64M0.01%May 31, 2026
Fidelity Extended Market Index Fund500,2430.51%$11.98M0.03%May 31, 2026
iShares Russell 2000 Value ETF496,6200.50%$16.58M0.11%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Emil D. KakkisPresident & CEO, Director2,694,7242.73%Apr 20, 2026
Howard HornChief Financial Officer89,2290.09%Oct 19, 2026
Theodore Alan HuizengaSVP, Chief Accounting Officer67,8630.07%Sep 15, 2026
Karah Herdman ParschauerEVP and Chief Legal Officer92,5620.09%Aug 4, 2026
Eric CrombezEVP and Chief Medical Officer111,1890.11%May 6, 2026
John Richard PinionSee Remarks133,1420.14%Apr 20, 2026
Dennis Karl HuangSee Remarks147,8450.15%Apr 20, 2026
Erik HarrisEVP & Chief Commercial Officer118,4100.12%Apr 20, 2026
Thomas Richard KassbergCBO & EVP265,2380.27%Mar 4, 2025
Corazon (Corsee) D. SandersDirector21,0950.02%Jun 15, 2026
Daniel G. WelchDirector40,4410.04%May 18, 2026
Michael NarachiDirector40,4410.04%May 18, 2026
Deborah DunsireDirector38,5660.04%May 18, 2026
Amrit RayDirector31,1160.03%May 18, 2026
Shehnaaz SulimanDirector27,9510.03%May 18, 2026
Matthew K. FustDirector33,6960.03%May 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Howard Horn
Chief Financial Officer
Oct 15, 2026Sale−7,066$15.27$107.90K89,229
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Sep 15, 2026Sale(10b5-1 plan)−1,283$13.57$17.41K67,863
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Sep 3, 2026Sale−161$13.99$2.25K69,146
Howard Horn
Chief Financial Officer
Aug 3, 2026Sale(10b5-1 plan)−4,696$24.92$117.02K96,295
Karah Herdman Parschauer
EVP and Chief Legal Officer
Aug 3, 2026Sale(10b5-1 plan)−1,900$24.92$47.35K92,562
Howard Horn
Chief Financial Officer
Jul 1, 2026Sale(10b5-1 plan)−4,698$33.13$155.64K100,991
Karah Herdman Parschauer
EVP and Chief Legal Officer
Jun 15, 2026Sale(10b5-1 plan)−1,899$24.62$46.75K94,462
Corazon (Corsee) D. Sanders
Director
Jun 15, 2026Sale−2,000$25.05$50.10K21,095
Howard Horn
Chief Financial Officer
Jun 1, 2026Sale(10b5-1 plan)−4,653$23.77$110.60K105,689
Shehnaaz Suliman
Director
May 18, 2026Sale(10b5-1 plan)−5,740$25.12$144.19K27,951
Shehnaaz Suliman
Director
May 14, 2026Award+7,751––33,691
Michael Narachi
Director
May 14, 2026Award+7,751––40,441
Daniel G. Welch
Director
May 14, 2026Award+7,751––40,441
Deborah Dunsire
Director
May 14, 2026Award+7,751––38,566
Corazon (Corsee) D. Sanders
Director
May 14, 2026Award+7,751––23,095
Amrit Ray
Director
May 14, 2026Award+7,751––31,116
Matthew K. Fust
Director
May 14, 2026Award+7,751––33,696
Eric Crombez
EVP and Chief Medical Officer
May 5, 2026Sale−344$24.96$8.59K111,189
Howard Horn
Chief Financial Officer
May 1, 2026Sale(10b5-1 plan)−4,683$24.90$116.61K110,342
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Apr 22, 2026Award+20,241––68,911
John Richard Pinion
See Remarks
Apr 16, 2026Award+23,116––133,142
Dennis Karl Huang
See Remarks
Apr 16, 2026Award+23,116––147,845
Eric Crombez
EVP and Chief Medical Officer
Apr 16, 2026Award+34,674––110,975
Howard Horn
Chief Financial Officer
Apr 16, 2026Award+34,674––115,025
Emil D. Kakkis
President & CEO, Director
Apr 16, 2026Award+76,745––735,739
Erik Harris
EVP & Chief Commercial Officer
Apr 16, 2026Award+28,895––118,410
Karah Herdman Parschauer
EVP and Chief Legal Officer
Apr 16, 2026Award+28,895––95,715
Howard Horn
Chief Financial Officer
Apr 1, 2026Sale(10b5-1 plan)−4,683$20.97$98.20K80,351
Karah Herdman Parschauer
EVP and Chief Legal Officer
Mar 10, 2026Sale−3,508$22.67$79.53K66,820
Karah Herdman Parschauer
EVP and Chief Legal Officer
Mar 6, 2026Sale−6,018$21.40$128.79K70,328
Howard Horn
Chief Financial Officer
Mar 3, 2026Sale(10b5-1 plan)−1,635$22.40$36.62K85,034
Howard Horn
Chief Financial Officer
Mar 2, 2026Sale(10b5-1 plan)−3,119$22.54$70.30K86,669
Howard Horn
Chief Financial Officer
Mar 2, 2026Sale(10b5-1 plan)−5,290$22.80$120.61K89,788
Emil D. Kakkis
President & CEO, Director
Mar 2, 2026Sale−54,404$22.80$1.24M658,994
Dennis Karl Huang
See Remarks
Mar 2, 2026Tax withholding−999$23.39$23.37K124,729
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Mar 2, 2026Tax withholding−148$23.39$3.46K50,302
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Mar 2, 2026Sale−1,632$22.80$37.21K48,670
Erik Harris
EVP & Chief Commercial Officer
Mar 2, 2026Sale−10,539$22.80$240.29K89,515
Karah Herdman Parschauer
EVP and Chief Legal Officer
Mar 2, 2026Sale−8,135$22.80$185.48K76,346
Eric Crombez
EVP and Chief Medical Officer
Mar 2, 2026Sale−7,029$22.80$160.26K76,301
John Richard Pinion
See Remarks
Mar 2, 2026Sale−10,029$22.80$228.66K110,026
Howard Horn
Chief Financial Officer
Mar 1, 2026Award+6,143––95,078
Emil D. Kakkis
President & CEO, Director
Mar 1, 2026Award+71,177––712,908
Dennis Karl Huang
See Remarks
Mar 1, 2026Award+11,137––125,728
Erik Harris
EVP & Chief Commercial Officer
Mar 1, 2026Award+11,643––99,498
Karah Herdman Parschauer
EVP and Chief Legal Officer
Mar 1, 2026Award+11,137––84,408
Eric Crombez
EVP and Chief Medical Officer
Mar 1, 2026Award+11,643––83,173
John Richard Pinion
See Remarks
Mar 1, 2026Award+11,137––119,565
Howard Horn
Chief Financial Officer
Feb 2, 2026Sale(10b5-1 plan)−3,061$23.56$72.12K88,935
Howard Horn
Chief Financial Officer
Jan 2, 2026Sale(10b5-1 plan)−3,150$22.84$71.95K91,996
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Dec 29, 2025Sale−85$34.38$2.92K50,450
Howard Horn
Chief Financial Officer
Dec 10, 2025Sale(10b5-1 plan)−3,081$36.38$112.09K95,146
Howard Horn
Chief Financial Officer
Oct 13, 2025Sale−7,942$31.51$250.25K98,227
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Sep 18, 2025Sale−64$29.17$1.87K50,242
Karah Herdman Parschauer
EVP and Chief Legal Officer
Sep 12, 2025Sale−2,450$31.17$76.37K73,271
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Sep 5, 2025Sale−84$31.39$2.64K50,306
Corazon (Corsee) D. Sanders
Director
Jun 20, 2025Sale(10b5-1 plan)−2,405$37.39$89.92K15,344
Matthew K. Fust
Director
May 15, 2025Award+5,740––25,945
Shehnaaz Suliman
Director
May 15, 2025Award+5,740––25,940
Corazon (Corsee) D. Sanders
Director
May 15, 2025Award+5,740––17,749

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
24.96%
24M shares short
Days to cover
8.3
At 3M shares a day
Change since last report
+17.3%
From 20M shares
Short volume, 20 days
40.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ultragenyx Pharmaceutical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 159,197 shares on Sep 3, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Theodore Alan Huizenga
Officer
Sep 15, 20261,283$17.46KSep 15, 2026Performance Stock Units
Howard Horn
Officer
Aug 3, 20264,696$117.02KAug 3, 2026Restricted Stock and Performance Shares
Howard Horn
Officer
Jul 1, 20264,698$155.64KJul 1, 2026Restricted Stock
Karah Herdman Parschauer
Officer
Jun 15, 20263,799$92.51KJun 15, 2026Performance Stock Units
Corazon (Corsee) D. Sanders
Director
Jun 15, 20262,000$50.10KJun 15, 2026Restricted Stock
Howard Horn
Officer
Jun 1, 20264,653$110.60KJun 1, 2026Performance and Restricted Stock
Shehnaaz Suliman
Director
May 18, 20265,740$144.19KMay 18, 2026Restricted Stock
Howard Horn
Officer
May 1, 20264,683$116.61KMay 1, 2026Restricted Stock
Howard Horn
Officer
Apr 1, 20264,683$98.20KApr 1, 2026Restricted Stock
Karah Herdman Parschauer
Officer
Mar 10, 20263,508$79.53KMar 10, 2026Restricted Stock
Karah Herdman Parschauer
Officer
Mar 6, 20266,018$128.77KMar 6, 2026Performance Shares
Howard Horn
Officer
Mar 3, 20261,635$36.62KMar 3, 2026Performance Shares
Howard Horn
Officer
Mar 2, 20263,119$70.30KMar 2, 2026Restricted Stock
Howard Horn
Officer
Feb 2, 20263,061$72.12KFeb 2, 2026Restricted Stock
Howard Horn
Officer
Jan 2, 20263,150$71.95KJan 2, 2026Restricted Stock

Congress trades

5 trades in Ultragenyx Pharmaceutical reported by 1 member of the House

MemberTypeTradedAmountFiled
Gilbert Cisneros
CA31
BoughtSep 29, 2026$1K–15KOct 12, 2026
Gilbert Cisneros
CA31
BoughtMar 3, 2026$1K–15KApr 7, 2026
Gilbert Cisneros
CA31
BoughtFeb 18, 2026$1K–15KMar 9, 2026
Gilbert Cisneros
CA31
BoughtAug 8, 2025$1K–15KSep 12, 2025
Gilbert Cisneros
CA31
BoughtJul 15, 2025$1K–15KAug 14, 2025

See a number that looks wrong?